NanoLogix, Inc. is a biotechnology company focused on the rapid detection and identification of viable microorganisms and viruses. Their innovative technologies include the use of specialized Petri plates packaged in a unique vacuum FlatPack® that extends shelf life significantly, allowing for long-term storage without refrigeration. This technology is applicable across various fields, including medical diagnostics, national defense, and environmental testing. Notably, NanoLogix has developed the Rapid Viral Assay, which enables quick and sensitive detection of viruses, including COVID-19, in under an hour. This assay distinguishes between live and inactive viral particles, reducing the risk of false positives commonly associated with traditional PCR methods.

In addition to viral detection, NanoLogix's N-Assay technology allows for the rapid identification of bacteria and their antibiotic resistance profiles. This technology has been recognized for its speed and accuracy, providing results in as little as four hours compared to conventional methods that can take days. The company’s advancements in live-cell diagnostics not only enhance the efficiency of medical treatments but also play a crucial role in pharmaceutical research and biodefense applications. By facilitating quicker diagnosis and treatment, NanoLogix aims to combat the growing issue of antibiotic resistance and improve public health outcomes.

United States

NanoLogix® is a biotechnology company that specializes in rapid diagnostics of viable microorganisms and viruses through petri plates with unique vacuum FlatPack® technology for extended shelf-life.

Nanologix

Company Details